Hyperactivation of PI3K-AKT signaling in cancer has formed the underlying basis for targeted therapies against this cascade that are currently in clinical development, including dual PI3K-mTOR inhibitors, PI3K inhibitors, AKT inhibitors, and mTOR complex catalytic site inhibitors [186]. Here, PIK3CA is linked to cancer.